CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...
BMS, says Kaiser, is tripling down on BCMA across different modalities. Multiple avenues for therapy Among these novel modalities, chimeric antigen receptor (CAR) T cells have the longest history ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback